Product Name :
Anti-Respiratory Syncytial Virus Glycoprotein F(Palivizumab Biosimilar) Antibody
Applications:
ELISA,Flow Cyt
Reactivity :
Respiratory Syncytial Virus Glycoprotein F
Conjugate:
Unconjugated
Advantages :
High lot-to-lot consistencyIncreased sensitivity and higher affinityAnimal-free production
Description:
| Description: Anti-Respiratory Syncytial Virus Glycoprotein F(Palivizumab Biosimilar) Antibody is a biosimilar antibody directed against Respiratory Syncytial Virus Glycoprotein F. | Isotype: Human IgG1 | Conjugate: Unconjugated | Specificity: Respiratory Syncytial Virus Glycoprotein F | Clonality: Monoclonal | Purity: Recombinant Expression and Affinity purified | Concentration: 1mg/ml | Formation: Liquid, 10mM PBS (pH 7.{{1431612-23-5} site|{1431612-23-5} Purity & Documentation|{1431612-23-5} Purity|{1431612-23-5} manufacturer} 5) | Storage: Store at –20 °C, (Avoid freeze/thaw cycles)
Description2 :
Anti-Respiratory Syncytial Virus Glycoprotein F(Palivizumab Biosimilar) Antibody is a biosimilar antibody directed against Respiratory Syncytial Virus Glycoprotein F.{{1345681-58-4} site|{1345681-58-4} Technical Information|{1345681-58-4} Formula|{1345681-58-4} supplier}
Immunogen:
Host :
Isotype:
Human IgG1
Purity :
Recombinant Expression and Affinity purified
Buffer :
Storage :
Function:
ELISA: 1:5000-1:20000Flow Cyt: 1:200-1:1000Other tested applications.PMID:20301318 Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
